Global Tissue Engineering Market - 2025-2033

The global tissue engineering market reached US$ 18.9 billion in 2024 and is expected to reach US$ 65.1 billion by 2033, growing at a CAGR of 14.9% during the forecast period 2025-2033.

Tissue engineering is an important tool in understanding how certain conditions progress and how they can be treated. It is part of the field of bioengineering, a broad discipline that combines principles from biology and engineering. Bioengineering is sometimes described as taking an engineering approach to the study of biology. Tissue engineering involves investigating the biological, physical, and chemical forces involved in tissue development, injury, and wound healing.

The goal of tissue engineering is to fabricate functional tissues and organs that can integrate seamlessly with the patient's body, ultimately improving patient outcomes and quality of life. This field encompasses various approaches, including scaffold-based techniques, cell-based therapies and bioactive molecule delivery systems.

The tissue engineering market is experiencing consistent growth with advancements in the field of tissue engineering and rising funding for tissue engineering. For instance, in November 2023, SPRIND Funke Tissue Engineering launched a ten-month journey to explore and demonstrate the key characteristics of artificial tissue embarking with four ambitious teams. SPRIND provided up to EUR 500,000 in funding to support this groundbreaking work.

Market Dynamics: Drivers & Restraints

Rising prevalence of chronic diseases

The rising prevalence of chronic diseases is significantly driving the growth of the tissue engineering market and is expected to drive the market over the forecast period. As chronic diseases such as diabetes, cardiovascular diseases, osteoarthritis and kidney disorders increase globally, the need for advanced treatment options, including tissue engineering, has grown.

For instance, according to the WHO, an estimated 17.9 million people die from cardiovascular diseases (CVDs) each year, making them the world's leading cause of mortality. The bulk of the 422 million individuals with diabetes globally reside in low- and middle-income nations, and the disease is directly responsible for 1.5 million fatalities annually. Around 1.71 billion people worldwide suffer from musculoskeletal disorders. The need for tissue engineering is expected to rise as a result of the rising incidence of numerous chronic illnesses.

Chronic diseases often lead to tissue damage or degeneration that traditional treatments cannot fully repair. Tissue engineering offers solutions by creating replacement tissues or organs, aiding in healing and regeneration. For instance, diabetic patients suffer from poor wound healing, necessitating tissue engineering for skin or vascular repair.

Additionally, developments in brain, lung, liver, and bone tissue engineering are useful for creating in vitro models of cancer metastasis. Because tissue engineering offers ways to directly examine carcinogenesis and migration at metastases, it has the potential to revolutionize cancer research. Since inducing angiogenesis is a key characteristic of cancer, neovascularization is frequently linked to the formation of solid tumors. Additionally, tissue engineering makes it possible to replicate the tumor microenvironment and all of its intricate and multifaceted features. Thus, rising cancer cases boosts the demand for tissue engineering.

High cost associated with the tissue engineering technique

The high cost associated with tissue engineering techniques is one of the major factors hampering the growth of the tissue engineering market. While tissue engineering holds promise for addressing chronic diseases and tissue damage, the costs involved in its development, production, and implementation are significant. For instance, according to the National Institute of Health (NIH), the total costs of stem cell-based tissue-engineered airway transplants for the three UK patients treated ranged from $174,420 to $740,500.

The development of bioprinted tissues using 3D printing technology is highly cost-intensive due to the need for specialized bioprinting machines, advanced biomaterials, and skilled technicians. While it holds significant potential, this technology is not yet affordable for widespread use. For instance, according to ResearchGate, bioprinting techniques prices range from $5,000 to over $500,000.

Segment Analysis

The global tissue engineering market is segmented based on material type, technology, application, end-user and region.

Technology:

The biomaterials and scaffolds segment is expected to dominate the tissue engineering market share

Biomaterials and scaffolds serve as the foundation for tissue regeneration by providing structural support for growing cells and promoting tissue formation. Biomaterials interact with biological systems to promote desired therapeutic outcomes, such as tissue regeneration, repair or replacement. In tissue engineering, biomaterials serve as scaffolds, carriers or matrices for cells and bioactive molecules, providing a supportive environment for tissue formation and integration. Thus, biomaterials and scaffolds are highly used for many research activities.

For instance, in November 2023, To conduct the research, Dr. ZHAO combined several disciplines, including material science, cell biology, engineering, and medicine. Her research focuses on modifying cell microenvironments, influencing cell behaviors, and promoting the growth of tissue-engineered organs. Her research team actively studies how cells perceive, interact, and evolve with biomaterials to restore diseased or damaged tissues to create patient-oriented biomaterials with distinctive shapes and properties.

Biomaterials serve as carriers for bioactive molecules, therapeutic agents or cells in tissue engineering applications. These biomaterials are used in bioprinting and pharmaceutical drug development. For instance, in September 2022, 3D Systems established Systemic Bio, a new, fully owned business. Systemic Bio will use biomaterials and human cells to produce incredibly accurate vascularized organ models by utilizing 3D Systems' innovative, production-level bioprinting technology. At the very beginning of the creation of new pharmaceutical drugs, these unique organs-on-chips can be produced in huge quantities with reproducible results and then perfused with any desired drug molecule to research drug metabolism and its effects on healthy or sick tissue.

Geographical Analysis

North America is expected to hold a significant position in the tissue engineering market share

North America is home to many leading companies in the tissue engineering space, which drive innovation and commercialization. These companies are involved in developing biomaterials, scaffolds, and cell-based therapies for various applications, including orthopedics, cardiovascular diseases, and wound healing.

Companies like Organovo, a leader in 3D bioprinting, Medtronic and other emerging players that develop advanced tissue engineering solutions, have strong presences in North America. The presence of these market leaders fosters a competitive environment that accelerates market growth.

For instance, in August 2024, CytoNest Inc. launched its first commercial product, a fiber scaffold that enhances tissue engineering and cell production. Applications for the product, known as CytoSurge 3D fiber scaffold, include cell research, biopharmaceutical cell therapies and the generation of cultured meat and seafood.

Asia-Pacific is growing at the fastest pace in the tissue engineering market

Tissue engineering in the Asia-Pacific region is expanding from research into clinical applications, with several companies and research institutions moving toward commercialization. The clinical application of tissue engineering technologies such as 3D bioprinting helps in treating conditions like skin burns, bone fractures, cartilage damage, organ failure and others are gaining momentum.

For instance, in November 2024, Scire Science, a biotech company based in Kochi, made history by introducing India's first patented domestic bioink for sophisticated 3D bioprinting applications. This invention positions Scire Science as an Indian leader in a field dominated by a small number of multinational corporations. With the use of sophisticated 3D bioprinting, this technique makes it possible to biofabricate the tissues of the liver, kidney, pancreas, skin, brain and heart.

Competitive Landscape

The major global players in the tissue engineering market include 3D BioFibR Inc., CollPlant Biotechnologies Ltd, Lonza Group, InSphero AG, Merck KGaA, Thermo Fisher Scientific Inc., Corning Incorporated, Prellis Biologics, Collagen Solutions (US) LLC, SunP BIOTECH, Cellink and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global tissue engineering market report delivers a detailed analysis with 73 key tables, more than 70 visually impactful figures, and 197 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.